Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000673665 | SCV000798893 | likely pathogenic | Mucopolysaccharidosis, MPS-III-B | 2018-03-27 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001218806 | SCV001390710 | pathogenic | Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease, axonal type 2V | 2019-06-01 | criteria provided, single submitter | clinical testing | This sequence change results in a premature translational stop signal in the NAGLU gene (p.Gln365*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 379 amino acids of the NAGLU protein. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with NAGLU-related conditions. ClinVar contains an entry for this variant (Variation ID: 557513). This variant disrupts the C-terminus of the NAGLU protein. Other variant(s) that disrupt this region (p.Arg626*) have been determined to be pathogenic (PMID: 9832037, 8650226, 10094189). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic. |